http://www.pharmaphorum.com/news/rb-spin-out-indivior-says-addiction-pipeline-will-deliver
“At the moment, patients have to decide every day whether to stay in treatment – that’s 365 dosing decisions every year – and we can reduce that down to 12.” The product is injected subcutaneously and forms a gel pellet that breaks down slowly over the course of a month…
A similar philosophy underpins Indivior’s new buprenorphine product based on a prodrug – called buprenorphine hemiadipate – which means it can be formulated into a swallowable rather than a sublingual tablet…
While these are all important new products from a clinical perspective, the biggest commercial opportunity will probably come from Indivior’s alcohol dependence treatment arbaclofen placarbil…
Thaxter also said that, as an independent company, Indivior will be actively looking for opportunities to expand its pipeline in the addiction arena with technologies applicable to alcohol, cocaine, methamphetamine and cannabis dependence, among others…
2/11/2015, Sales slump for Reckitt pharma spinoff Indivior in its first-ever earnings release
https://clinicaltrials.gov/ct2/show/NCT01848054
5/2/2013, Study to Assess OX219 (Buprenorphine/Naloxone) for the Induction of Treatment of Opioid Dependence
OX219 (Buprenorphine/Naloxone) [Zubsolv®]
Principal Investigator: Lynn Webster Life Tree Pain Clinic, 3838 S 700 E Suite 200, Salt Lake City, UT 84106
Sponsor: Orexo AB
No Study Results Posted on ClinicalTrials.gov for this Study
Study Completion Date: January 2014
7/1/2010, Purdue Pharma L.P. Receives FDA Approval for Butrans™ (buprenorphine) Transdermal System CIII
“Healthcare professionals now have an important new option for appropriate adult patients suffering from moderate to severe chronic pain when an opioid may be needed to manage their pain,” said Lynn R. Webster, MD, FACPM, FASAM, Medical Director of the Lifetree Clinical Research and Pain Clinic in Salt Lake City, Utah…
http://www.bizjournals.com/prnewswire/press_releases/2011/03/25/NY71789
SAN CARLOS, Calif., March 25, 2011 /PRNewswire/ — PharmacoFore, Inc., a privately held biopharmaceutical company developing next-generation abuse-resistant prescription drugs, announced that Lynn R. Webster, M.D., FACPM, FASAM, Co-Founder and Medical Director of Lifetree Clinical Research, will introduce the Company’s novel technology during the 27th Annual American Academy of Pain Medicine (AAPM) Meeting.
Dr. Webster’s presentation, titled “New Opioid Formulations and Delivery Systems,” will feature PharmacoFore’s Bio-Activated Molecular Delivery™ (also referred to as Bio-MD™) and MPAR™ technologies…
BUNAVAIL utilizes BDSI’s proprietary BioErodible MucoAdhesive (BEMA) technology to deliver buprenorphine for the maintenance treatment of opioid dependence, along with the opioid antagonist naloxone, which is intended to serve as an abuse deterrent…
Poster presentation by Lynn Webster, MD
Low-Dose Naloxone Provides an Abuse Deterrent Effect to Buprenorphine Doses
BEMA Buprenorphine is in Phase 3 clinical trials for the treatment of moderate to severe chronic pain and is licensed on a worldwide basis to Endo Pharmaceuticals. Clonidine Topical Gel for the treatment of painful diabetic neuropathy is currently in Phase 3 development…
http://www.drugandalcoholdependence.com/article/S0376-8716(14)01686-X/abstract
Abuse potential study of intravenous oxycodone hydrochloride alone or in combination with intravenous naltrexone in nondependent, recreational opioid users
ALO-02 is an opioid formulation intended to deter abuse; it comprises capsules filled with pellets of extended-release oxycodone hydrochloride surrounding sequestered naltrexone. The abuse potential (i.e., drug liking and high) of intravenous (IV) oxycodone combined with naltrexone, to simulate IV administration of crushed ALO-02 in solution, was compared with IV oxycodone alone and IV placebo in nondependent, recreational opioid users.
http://www.drugandalcoholdependence.com/article/S0376-8716(14)01706-2/abstract
Preliminary report of THC influence on subject ability to discriminate between active opioid and placebo in human abuse liability study
http://www.opioidrisk.com/node/884
ORT: Opioid Risk Tool
Reprinted With Permission from Lynn Webster, MD
Click to access presidents-message-2014-volume15-3.pdf
(2014) Pain and Suicide: The Other Side of the Opioid Story
Three days later I got a call from his daughter. Jack had died from a self-inflicted gunshot wound. He left a note saying he couldn’t live with the pain anymore…
All Things Chronic 
One thought on “11/21/2014, RB spin-out Indivior says addiction pipeline will deliver”